Literature DB >> 17650451

The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone.

Faith E Davies, Ping Wu, Matthew Jenner, Muralikrishan Srikanth, Radovan Saso, Gareth J Morgan.   

Abstract

The combination of bortezomib (velcade), pulsed dexamethasone and weekly cyclophosphamide (CVD) in relapsed/refractory myeloma patients induces high overall (75%) and complete (31%) response rates compared to velcade/dexamethasone (overall 47%, CR 5%) and velcade alone (overall 27%, CR 0%). The toxicity profiles including thrombocytopenia, neutropenia, and neuropathy were comparable between the groups.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17650451     DOI： 10.3324/haematol.11228

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  21 in total

1.  Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).

Authors:  Arnaud Jaccard; Raymond L Comenzo; Parameswaran Hari; Philip N Hawkins; Murielle Roussel; Pierre Morel; Margaret Macro; Jean-Luc Pellegrin; Estibaliz Lazaro; Dania Mohty; Patrick Mercie; Olivier Decaux; Julian Gillmore; David Lavergne; Frank Bridoux; Ashutosh D Wechalekar; Christopher P Venner
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

2.  Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma.

Authors:  Isamu Sugiura; Satomi Terabe; Tomohiro Kinoshita; Kazuhito Yamamoto; Masashi Sawa; Yukiyasu Ozawa; Yoshiko Atsuta; Ritsuro Suzuki; Kazuyuki Shimizu
Journal:  Int J Hematol       Date:  2015-08-23       Impact factor: 2.490

3.  Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Authors:  E K Mai; U Bertsch; J Dürig; C Kunz; M Haenel; I W Blau; M Munder; A Jauch; B Schurich; T Hielscher; M Merz; B Huegle-Doerr; A Seckinger; D Hose; J Hillengass; M S Raab; K Neben; H-W Lindemann; M Zeis; C Gerecke; I G H Schmidt-Wolf; K Weisel; C Scheid; H Salwender; H Goldschmidt
Journal:  Leukemia       Date:  2015-03-19       Impact factor: 11.528

Review 4.  Advances in treatment for relapses and refractory multiple myeloma.

Authors:  Tiffany Richards; Donna Weber
Journal:  Med Oncol       Date:  2010-03-06       Impact factor: 3.064

5.  Durable remission with salvage second autotransplants in patients with multiple myeloma.

Authors:  Nina Shah; Fraz Ahmed; Qaiser Bashir; Sofia Qureshi; Yvonne Dinh; Gabriela Rondon; Sijin Wen; Peter Thall; Hassan Khan; Sergio Giralt; Richard Champlin; Muzaffar H Qazilbash
Journal:  Cancer       Date:  2011-11-15       Impact factor: 6.860

Review 6.  New immunomodulatory drugs in myeloma.

Authors:  Martha Q Lacy
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

7.  Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.

Authors:  Britta Auel; Hartmut Goldschmidt; Thomas Geer; Thomas M Moehler; Uwe Platzbecker; Ralph Naumann; Igor Blau; Mathias Hänel; Wolfgang Knauf; Holger Nückel; Hans-Jürgen Salwender; Christof Scheid; Katja Weisel; Marcus Gorschlüter; Axel Glasmacher; Ingo G H Schmidt-Wolf
Journal:  Indian J Hematol Blood Transfus       Date:  2011-08-18       Impact factor: 0.900

8.  Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.

Authors:  David C Johnson; Sophie Corthals; Christine Ramos; Antje Hoering; Kim Cocks; Nicholas J Dickens; Jeff Haessler; Harmut Goldschmidt; J Anthony Child; Sue E Bell; Graham Jackson; Dalsu Baris; S Vincent Rajkumar; Faith E Davies; Brian G M Durie; John Crowley; Pieter Sonneveld; Brian Van Ness; Gareth J Morgan
Journal:  Blood       Date:  2008-09-19       Impact factor: 22.113

9.  Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.

Authors:  Aldo M Roccaro; Irene M Ghobrial; Simona Blotta; Steven P Treon; Michele Malagola; Kenneth C Anderson; Paul G Richardson; Domenico Russo
Journal:  Biologics       Date:  2008-09

Review 10.  New therapies in multiple myeloma.

Authors:  F Merchionne; F Perosa; F Dammacco
Journal:  Clin Exp Med       Date:  2007-10-03       Impact factor: 3.984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.